Literature DB >> 8253126

Characterization of [3H]meta-chlorophenylbiguanide binding to 5-HT3 receptors in N1E-115 neuroblastoma cells.

S C Lummis1, M I Sepúlveda, G J Kilpatrick, J Baker.   

Abstract

The binding characteristics of a radiolabelled 5-HT3 receptor agonist, [3H]meta-chlorophenylbiguanide (mCPBG), were examined in membranes from N1E-115 neuroblastoma cells. Scatchard plots of saturation binding data showed the presence of two populations of binding sites, with Kd = 0.03 +/- 0.01 nM and 4.4 +/- 1.2 nM and Bmax = 11.9 +/- 4.2 and 897.9 +/- 184.7 fmol/mg protein respectively. Competition studies with a selection of agonists and antagonists revealed the pharmacological profile expected for a 5-HT3 receptor. The rank order of potency for antagonists was granisetron > quipazine > GR65630 > ondansetron > MDL72222, and for agonists was mCPBG > 5-HT (5-hydroxytryptamine, serotonin) > 2-methyl-5-HT. IC50 values for 5-HT and 2-methyl-5-HT were lower than those observed using radiolabelled antagonists, and combined with functional experiments, the data suggest that [3H]mCPBG may label high affinity desensitized states of the receptor. We conclude that [3H]mCPBG labels 5-HT3 receptors in N1E-115 neuroblastoma cell membranes and may be a useful compound with which to explore 5-HT3 receptors in other systems.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8253126     DOI: 10.1016/0014-2999(93)90160-j

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Characterization of 5-HT3 receptor mutations identified in schizophrenic patients.

Authors:  Andrew J Thompson; Nora L Sullivan; Sarah C R Lummis
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  A single ring of charged amino acids at one end of the pore can control ion selectivity in the 5-HT3 receptor.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

3.  Defining the roles of Asn-128, Glu-129 and Phe-130 in loop A of the 5-HT3 receptor.

Authors:  Nora L Sullivan; Andrew J Thompson; Kerry L Price; Sarah C R Lummis
Journal:  Mol Membr Biol       Date:  2006 Sep-Oct       Impact factor: 2.857

Review 4.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

Review 5.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

6.  Calcium modulation of 5-HT3 receptor binding and function.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Neuropharmacology       Date:  2008-07-16       Impact factor: 5.250

7.  Selection of distinct conformational states of the 5-HT3 receptor by full and partial agonists.

Authors:  J A van Hooft; H P Vijverberg
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

8.  The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT3 receptors.

Authors:  A J Thompson; M Lochner; S C R Lummis
Journal:  Br J Pharmacol       Date:  2007-05-14       Impact factor: 8.739

9.  5-Fluorotryptamine is a partial agonist at 5-HT3 receptors, and reveals that size and electronegativity at the 5 position of tryptamine are critical for efficient receptor function.

Authors:  Kiowa S Bower; Kerry L Price; Laura E C Sturdee; Mariza Dayrell; Dennis A Dougherty; Sarah C R Lummis
Journal:  Eur J Pharmacol       Date:  2007-11-17       Impact factor: 4.432

10.  Identification of critical residues in loop E in the 5-HT3ASR binding site.

Authors:  Padmavati Venkataraman; Srinivasan P Venkatachalan; Prasad R Joshi; Mani Muthalagi; Marvin K Schulte
Journal:  BMC Biochem       Date:  2002-06-13       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.